Bicitropeptide and cimetidine in the treatment of duodenal ulcers. A double-blind, double-dummy endoscopically controlled trial.

Abstract

In a double-blind endoscopic study of 55 patients with uncomplicated duodenal ulcers, treatment with the mucosal-protective agent, bicitropeptide (BCP-Compound), was superior to that with cimetidine (Tagamet) after 6 weeks. After the administration of bicitropeptide, 77% of ulcers had completely healed and 25% had partially healed, and after treatment with cimetidine 38% had completely healed and 38% had partially healed (chi 2 = 6,316; P < 0,025). There was no difference between the results of treatment with either drug at 12 weeks. Patients were followed up 3 months after the ulcers healed, and 44% who had been on bicitropeptide and 72% on cimetidine had active ulcers (no significant difference). Blood and urine bismuth levels were estimated before therapy, after 6 weeks of therapy, and after 3 months without therapy. Results showed that in patients taking bicitropeptide, urine bismuth levels rose significantly between 0 and 6 weeks, but decreased to pretreatment levels after 3 months without therapy. Blood bismuth levels did not change.

• Authors: M G Moshal, J M Spitaels, F Khan
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 58 Issue 16 Pg. 631-3 (Oct 18 1980) ISSN: 0256-9574 [Print] South Africa
• PMID: 6999640 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Ulcer Agents
• Guanidines
• Metalloproteins
• Proteins
• bicitropeptide
• Cimetidine
• Bismuth

Topics

• Adult
• Anti-Ulcer Agents (therapeutic use)
• Bismuth (therapeutic use)
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (drug therapy)
• Guanidines (therapeutic use)
• Humans
• Metalloproteins
• Proteins (therapeutic use)